Business Wire

Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs

28.6.2017 11:30 | Business Wire

Del

Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.

Ms. Steele, who brings more than 25 years of public affairs experience to Biogen, will lead the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts.

“Catherine is joining us at an exciting time in the evolution of Biogen,” said Chief Executive Officer Michel Vounatsos. “As we strengthen our pipeline, reaffirm our commitment to neuroscience and look to enter new therapeutic areas and markets globally, Catherine will play a crucial role in helping align our business with key public and patient audiences and establish Biogen with new stakeholders globally.”

Ms. Steele most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company’s social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.

"I am privileged to join Biogen, a respected and recognized pioneer in neuroscience," said Ms. Steele. "I look forward to building upon that legacy and being part of this company whose commitment to patients, families and society affected by neurological diseases is unwavering."

Ms. Steele holds dual undergraduate degrees in French and political science from the University of New Brunswick and a Master of Arts degree in political science from Carleton University.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Contact information

Biogen
MEDIA CONTACT:
Matt Fearer, +1 781-464 3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1-781-464-2442
IR@biogen.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

PacSci EMC Competes on National Stage as NASA iTech Innovation Competition Finalist20.7.2017 21:45Pressemelding

PacSci EMC recently participated as a finalist in NASA’s second iTech Forum, competing to have their innovative idea selected as one of the top 10 in a yearlong initiative to find and foster innovative solutions with the potential to benefit NASA and the nation in the future. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720006386/en/ Douglas Terrier, Acting Chief Technologist, NASA presents Peter Current, Steve Nelson, and Bret Omsberg with a certificate recognizing “PacSci EMC as a top 10 finalist of NASA iTech’s Cycle 2 on July 13, 2017.” Photo Credit: NASA The teams competed against entrepreneurs presenting their proposed solutions to tough technology challenges to judges consisting of NASA’s chief technologists, space industry leaders and potential investors. Hosted by the National Institute of Aerosp

Insulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe20.7.2017 20:01Pressemelding

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced plans to assume, on July 1, 2018, the distribution, sales, marketing, training and support activities of Insulet’s Omnipod System across Europe following the expiration of the Company’s global distribution agreement with Ypsomed AG (Ypsomed) on June 30, 2018. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720006257/en/ Insulet develops, manufactures and distributes the Omnipod System, the market-leading tubeless insulin management system, currently used by over 110,000 people living with diabetes worldwide. Since 2010, the Company has had an exclusive contract with Ypsomed to distribute Insulet’s Omnipod System across Europe

Natalia Vodianova Joins PicsArt as Head of Aspiration20.7.2017 13:00Pressemelding

PicsArt, the leading image editing app and creative social network, today announced the appointment of Natalia Vodianova, the supermodel and philanthropist, as Head of Aspiration. In this new role, Natalia will inspire and suggest opportunities to drive positive change through creativity. She has also joined the company’s advisory board. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005372/en/ Natalia Vodianova, the supermodel and philanthropist, joins PicsArt as Head of Aspiration. (Photo: Business Wire) “We are thrilled to welcome a talent and role model like Natalia into our family,” said PicsArt CEO Hovhannes Avoyan. “Natalia has been deeply involved in bringing creative inspiration to the world through fashion and social commitment. She’ll help connect the fashion world and the

Pacific Drilling Announces Early Consent Deadline Results20.7.2017 13:00Pressemelding

Pacific Drilling V Limited (the “Issuer”), a wholly owned subsidiary of Pacific Drilling S.A. (NYSE: PACD) (together with its subsidiaries, the “Company”) announced today the results, as of 5:00 p.m. Eastern Daylight Time on July 19 (the “Early Consent Deadline”) of its previously announced private consent solicitation in respect of its 7.25% Senior Secured Notes due December 1, 2017 (the “Notes”) pursuant to which the Issuer is soliciting the consent of the holders of Notes to an extension of the maturity date of the Notes to June 1, 2018 in order to give the Company more time to negotiate a refinancing transaction or undertake a holistic restructuring with all of its creditors (the “Solicitation”). At the Early Consent Deadline, the Issuer has received consents of holders of the Notes comprising less than 66 2/3% of the aggregate principal amount of the Notes (disregarding Notes held by the

CloudHealth Technologies Expands Business in Europe20.7.2017 13:00Pressemelding

CloudHealth Technologies, the leader in cloud service management, today announced that it is expanding its customer base, partner list and business operations in the European region. Helping to fuel the expansion is $46 million in Series D funding, which the company secured in June. The funding round will help CloudHealth Technologies scale international operations and double the size of its global workforce. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005189/en/ CloudHealth Technologies Expands Business in Europe (Photo: Business Wire) Cloud adoption in EMEA is growing steadily, with the market projected to reach €44.8 billion by the year 2020, according to Market Research & Statistics1. As enterprises turn to the cloud to build apps and manage operations, they improve

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom